![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
INTEGRATED EFFICACY ANALYSIS OF FOUR PHASE 3 STUDIES IN HCV GENOTYPE 1A-INFECTED PATIENTS TREATED WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN
|
|
|
Reported by Jules Levin
AASLD 2014 Boston Nov 9
Gregory T. Everson, Geoffrey Dusheiko, Eoin Coakley, Stephen Shafran, Fabien Zoulim, Moisés Diago, Ravi Ravinuthala, Suzanne Norris, Bo Fu, Roger Trinh, Yan Luo, Thomas Podsadecki, Mark S. Sulkowski
![AASLD1.gif](../images/111014/111014-4/AASLD1.gif)
![AASLD2.gif](../images/111014/111014-4/AASLD2.gif)
![AASLD3.gif](../images/111014/111014-4/AASLD3.gif)
![AASLD4.gif](../images/111014/111014-4/AASLD4.gif)
![AASLD5.gif](../images/111014/111014-4/AASLD5.gif)
![AASLD6.gif](../images/111014/111014-4/AASLD6.gif)
![AASLD7.gif](../images/111014/111014-4/AASLD7.gif)
![AASLD8.gif](../images/111014/111014-4/AASLD8.gif)
![AASLD9.gif](../images/111014/111014-4/AASLD9.gif)
![AASLD10.gif](../images/111014/111014-4/AASLD10.gif)
![AASLD11.gif](../images/111014/111014-4/AASLD11.gif)
![AASLD12.gif](../images/111014/111014-4/AASLD12.gif)
![AASLD13.gif](../images/111014/111014-4/AASLD13.gif)
![AASLD14.gif](../images/111014/111014-4/AASLD14.gif)
![AASLD15.gif](../images/111014/111014-4/AASLD15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|